221 related articles for article (PubMed ID: 36199423)
1. Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Ding L; Ning S; Hu W; Xue Y; Yu S
Oxid Med Cell Longev; 2022; 2022():6595989. PubMed ID: 36199423
[TBL] [Abstract][Full Text] [Related]
2. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
3. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
4. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
7. Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.
Wu L; Yang J; Ke RS; Liu Y; Guo P; Feng L; Li Z
Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):101999. PubMed ID: 35870795
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Jiang S; Lu H; Pan Y; Yang A; Aikemu A; Li H; Hao R; Huang Q; Qi X; Tao Z; Wu Y; Quan C; Zhou G; Lu Y
Cancer Lett; 2024 Apr; 588():216799. PubMed ID: 38479553
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.
Wang L
Tumour Biol; 2013 Jun; 34(3):1679-84. PubMed ID: 23532688
[TBL] [Abstract][Full Text] [Related]
11. Integrative Analysis of ceRNA Network Reveals Functional lncRNAs in Intrahepatic Cholangiocarcinoma.
Zhou D; Gao B; Yang Q; Kong Y; Wang W
Biomed Res Int; 2019; 2019():2601271. PubMed ID: 31886187
[TBL] [Abstract][Full Text] [Related]
12. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
13. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
Zhou YW; Li QF; Chen YY; Wang K; Pu D; Chen XR; Li CH; Jiang L; Wang Y; Li Q; Yang Y; Gou HF; Bi F; Liu JY; Chen Y; Qiu M
Eur J Surg Oncol; 2022 Jul; 48(7):1559-1566. PubMed ID: 35115213
[TBL] [Abstract][Full Text] [Related]
18. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
Wu C; Bai DS; Jiang GQ; Jin SJ
World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract][Full Text] [Related]
20. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
